Evidence map›Paper›PMID 19216902›Full record

ArticleMethods in enzymology2009

Assessing metabolic stress and autophagy status in epithelial tumors.

Robin Mathew, Vassiliki Karantza-Wadsworth, Eileen White

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Methods in enzymology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03254888 (Identification of Novel Autophagy Markers in Bladder Cancer Patients), which is not on this map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
9.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03254888 unknown statusnot on this mapstarted 2020, after this paper: background citation

Identification of Novel Autophagy Markers in Bladder Cancer Patients

TypeobservationalSponsorAssiut UniversityRan2020 to 2021Enrolled150ConditionsBladder Cancer
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Autophagy genes as tumor suppressors.Current opinion in cell biology · 2010
    Review
  17. The double-edged sword of autophagy modulation in cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Robin MathewUniversity of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey, USA.
Vassiliki Karantza-Wadsworth
Eileen White
Johnson University · USRutgers Cancer Institute of New JerseyRutgers, The State University of New Jersey · US

Funding

Role of Autophagy in CancerR01CA130893 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI WHITE, EILEEN P. · 2008 to 2017
$3.4M
Role of Autophagy in Breast CancerR00CA133181 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI KARANTZA, VASSILIKI · 2009 to 2011
$734k
NCI NIH HHS R00 CA133181NCI NIH HHS R01 CA130893
6 · The paper itself

Abstract

Autophagy is a survival mechanism activated in response to metabolic stress. In normal tissues autophagy plays a major role in energy homeostasis through catabolic self-digestion of damaged proteins and organelles. Contrary to its survival function, autophagy defects are implicated in tumorigenesis suggesting that autophagy is a tumor suppression mechanism. Although the exact mechanism of this tumor suppressor function is not known, it likely involves mitigation of cellular damage leading to chromosomal instability. The complex role of functional autophagy in tumors calls for model systems that allow the assessment of autophagy status, stress management and the impact on oncogenesis both in vitro as well as in vivo. We developed model systems that involve generation of genetically defined, isogenic and immortal epithelial cells from different tissue types that are applicable to both wild-type and mutant mice. This permits the study of tissue- as well as gene-specific tumor promoting functions. We successfully employed this strategy to generate isogenic, immortal epithelial cell lines from wild-type and mutant mice deficient in essential autophagy genes such as beclin 1 (beclin 1(+/-)) and atg5 (atg 5(-/-)). As these cell lines are amenable to further genetic manipulation, they allowed us to generate cell lines with apoptosis defects and stable expression of the autophagy marker EGFP-LC3 that facilitate in vitro and in vivo assessment of stress-mediated autophagy induction. We applied this model system to directly monitor autophagy in cells and 3D-morphogenesis in vitro as well as in tumor allografts in vivo. Using this model system we demonstrated that autophagy is a survival response in solid tumors that co-localizes with hypoxic regions, allowing tolerance to metabolic stress. Furthermore, our studies have established that autophagy also protects tumor cells from genome damage and limits cell death and inflammation as possible means to tumor suppression. Additionally these cell lines provide an efficient way to perform biochemical analyses, and high throughput screening for modulators of autophagy for potential use in cancer therapy and prevention.

Indexed as

AnimalsAutophagyCells, CulturedEpithelial CellsMiceMicrotubule-Associated ProteinsNeoplasmsStress, PhysiologicalMap1lc3b protein, mouseMicrotubule-Associated Proteins

Identifiers

PMID19216902
PMCPMC2857509
OpenAlexW1545448140

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.